Green Cross to conduct Phase I trial for DNA recombinant product

Published: 2008-03-27 06:57:00

Updated: 2008-03-27 06:57:00

Green Cross Corporation plans to carry out its Phase I study to evaluate a new DNA recombinant drug Hepabig-Gene, which was approved by the Korean Food and Drug Administration.

The Phase I study for Hepabig-Gene is an open, comparative, increased dose clinical trial at the general surgery depa...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK